Abstract
Objectives
The purpose of this study was to compare approved first-line therapies for patients with multiple myeloma.
Methods
A systematic literature search for phase III randomized controlled trials (RCTs) comparing first-line chemotherapies approved in Germany and recommended by guidelines at the time of study design was conducted. Random-effects meta-analysis (MA) was used for direct and the Bucher method for adjusted indirect treatment comparison.
Results
One RCT comparing melphalan and prednisone plus bortezomib (VMP) vs. melphalan and prednisone (MP) and six RCTs comparing MP plus thalidomide (MPT) vs. MP were analysed. For MPT vs. MP, an individual patient data (IPD) MA was used for sensitivity analyses. VMP and MPT were superior to MP regarding efficacy endpoints (VMP vs. MP, overall survival (OS): hazard ratio (HR) 0.70, 95 % confidence interval (CI) 0.57–0.86; progression-free survival (PFS): HR 0.56, 0.39–0.79; complete response (CR), risk-ratio (RR) for non-response: 0.70, 0.65–0.75; MPT vs. MP, OS: HR 0.83, 0.66–1.03; PFS: HR 0.67, 0.56–0.81; CR, RR for non-response 0.92, 0.88–0.95); but had a higher risk of developing any grade 3–4 adverse events (AEs) (VMP vs. MP: RR 1.13, 1.06–1.20; MPT vs. MP: RR 2.06, 1.43–2.98). The indirect comparison of VMP vs. MPT via MP showed a statistically not significant advantage for VMP regarding survival outcomes (OS: HR 0.85, 0.63–1.14; PFS: HR 0.83, 0.56–1.23) and a significant advantage regarding CR (RR for non-response 0.76, 0.70–0.83) and AEs (RR 0.55, 0.38–0.80). Treatment comparisons using results of IPD MA yielded similar effect sizes.
Conclusions
VMP and MPT seem more effective than MP, VMP was superior to MPT regarding response criteria and AEs. Our results may best be confirmed by a head-to-head trial of VMP vs. MPT.
Similar content being viewed by others
References
Bundesministerium für Gesundheit (2010) Gesetz zur Neuordnung des Arzneimittelmarktes in der gesetzlichen Krankenversicherung (Arzneimittelmarktneuordnungsgesetz – AMNOG). Bundesgesetzblatt 67:2262–2277
Kaiser T, Vervölgyi V, Wieseler B (2015) Nutzenbewertung von Arzneimitteln. Bundesgesundheitsblatt 58:232–239. doi:10.1007/s00103-014-2110-5
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2015) General methods: version 4.2. https://www.iqwig.de/download/IQWiG_General_Methods_Version_%204-2.pdf. Accessed 10. Nov. 2015
Lebioda A, Gasche D, Dippel F-W, Theobald K, Plantör S (2014) Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland. Heal Econ Rev 4(1):31. doi:10.1186/s13561-014-0031-5
Fonseca R, Monge J (2013) Myeloma: classification and risk assessment. Semin Oncol 40(5):554–566. doi:10.1053/j.seminoncol.2013.07.002
Spicka I (2014) Advances in multiple myeloma therapy during two past decades. Comput Struct Biotechnol J 10(16):38–40. doi:10.1016/j.csbj.2014.05.005
Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey WJ Jr, Wilson HE (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208(9):1680–1685
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012. doi:10.1016/j.jclinepi.2009.06.005
Kortüm M, Driessen C, Einsele H, Goldschmidt H, Gunsilius E, Kröger N, Kropff M, Liebisch P, Ludwig H, Naumann R, Peest D, Taverna C, Wörmann BJ (2013) Multiples myelom. leitlinie. DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. https://www.dgho-onkopedia.de/de/onkopedia/leitlinien/multiples-myelom. Accessed 05. Aug. 2015
National Institute for Health and Care Excellence (2012) Single technology appraisal. Specification for manufacturer/sponsor submission of evidence. https://www.nice.org.uk/proxy/?sourceUrl=http%3a%2f%2fwww.nice.org.uk%2fmedia%2fD54%2f6E%2fSpecificationForManufacturerSponsorSubmissionOfEvidenceJune2012.doc. Accessed 05 Aug. 2015
Higgins JP, Green S (2008) Cochrane handbook for systematic reviews of interventions, Cochrane Book Series. Wiley-Blackwell, Oxford
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50(6):683–691
Caldwell DM, Welton NJ, Ades AE (2010) Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. J Clin Epidemiol 63(8):875–882. doi:10.1016/j.jclinepi.2009.08.025
Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC (2011) Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14(4):417–428. doi:10.1016/j.jval.2011.04.002
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. doi:10.1136/bmj.327.7414.557
StataCorp (2011) Stata statistical software: release 12. StataCorp LP, College Station
Harris RJ, Bradburn MJ, Deeks JJ, Harbord RM, Altman DG, Sterne JAC (2008) Metan: fixed- and random-effects meta-analysis. Stata J 8(1):3–28
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG, Investigators VT (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906–917. doi:10.1056/NEJMoa0801479
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG (2013) Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 31(4):448–455. doi:10.1200/JCO.2012.41.6180
Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H, Intergroupe Francophone du M (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 370(9594):1209–1218. doi:10.1016/S0140-6736(07)61537-2
Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M, G Italian Multiple Myeloma Network (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513):825–831. doi:10.1016/S0140-6736(06)68338-4
Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, Montanaro M, Ria R, Capaldi A, Zambello R, Benevolo G, Derudas D, Dore F, Cavallo F, Gay F, Falco P, Ciccone G, Musto P, Cavo M, Boccadoro M (2008) Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112(8):3107–3114. doi:10.1182/blood-2008-04-149427
Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azais I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27(22):3664–3670. doi:10.1200/JCO.2008.21.0948
Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst H, Sonneveld P, Dutch-Belgium Cooperative Group H (2010) Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 28(19):3160–3166. doi:10.1200/JCO.2009.26.1610
Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Bjorkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukas E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sorbo JH, Wisloff F, Juliusson G, Turesson I, Nordic Myeloma Study G (2010) Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116(9):1405–1412. doi:10.1182/blood-2009-08-237974
Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H, Aydogdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L (2011) Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 86(1):16–22. doi:10.1111/j.1600-0609.2010.01524.x
Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksac M, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T, Nordic Myeloma Study G, Italian Multiple Myeloma N, Turkish Myeloma Study G, Hemato-Oncologie voor Volwassenen N, Intergroupe Francophone du M, European Myeloma N (2011) Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118(5):1239–1247. doi:10.1182/blood-2011-03-341669
Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pegourie B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld P (2013) Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica 98(1):87–94. doi:10.3324/haematol.2012.067058
Kumar A, Hozo I, Wheatley K, Djulbegovic B (2011) Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. Am J Hematol 86(1):18–24. doi:10.1002/ajh.21904
Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omede P, Zweegman S, Jose Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M (2014) Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. Am J Hematol 89(4):355–362. doi:10.1002/ajh.23641
Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Blade J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA, Investigators MM (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366(19):1759–1769. doi:10.1056/NEJMoa1112704
Yang B, Yu RL, Chi XH, Lu XC (2013) Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS One 8(5):e64354. doi:10.1371/journal.pone.0064354
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2015) Dulaglutid (Trulicity®) - Nutzenbewertung gemäß § 35a SGB V, A15-07. https://www.g-ba.de/downloads/92-975-778/2015-04-29_Nutzenbewertung-IQWiG_Dulaglutid.pdf. Accessed 10. Nov. 2015
Authors’ contributions
KK, DW, MH and WL made substantial contributions to conception and design of this work. KS performed the initial systematic literature research, KK and DW updated it and selected relevant studies. KK and MH extracted data using results of KS and the original publications of eligible studies. KK and MH did the analysis, and DW and WL took part in the interpretation of the analysis. KK and DW drafted the manuscript. All authors made substantial contributions to creation of the final manuscript and revised the final draft of the manuscript critically for important intellectual content. All authors gave final approval of the version to be published.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was funded by Janssen-Cilag GmbH, Neuss, Germany.
Conflicts of interest
KK and MH report grants from Janssen-Cilag, during the conduct of the study. WL reports grants from Janssen-Cilag, during the conduct of the study; personal fees from Janssen-Cilag for statistical courses, outside the submitted work. DW states being an employee of Janssen-Cilag. KS was working with HERON Health Pvt. Ltd., during the conduct of the study. HERON is a consultancy which was hired to conduct systematic reviews by Janssen. KS now works with BresMed Health Solutions. No other relationships or activities that may appear to have influenced the submitted work are declared.
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(PDF 189 kb)
Rights and permissions
About this article
Cite this article
Kuhr, K., Wirth, D., Srivastava, K. et al. First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany. Eur J Clin Pharmacol 72, 257–265 (2016). https://doi.org/10.1007/s00228-015-1998-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-015-1998-5